Expert Interview
Examining Coherus' Udenyca, the FDA-approved pegfilgrastim biosimilar prefilled autoinjector administered the day after chemotherapy to lower the risk of infection
Ticker(s): CHRSInstitution: University of Colorado
- Chair in Cancer Research, Distinguished Professor, Medicine-Medical Oncology, & Founding Director of the University of Colorado Cancer Center.
- Past president of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO); served as chairman of the FDA Oncology Drug Advisory Committee.
- Currently managing 4 patients with mesothelioma.
- Research focuses on novel molecular therapies and immunotherapies for lung cancer and other thoracic cancers.
Please describe your background and practice experience
Added By: ben_adminHow many patients undergoing myelosuppressive chemotherapy do you manage?
Added By: ben_adminWhat percentage of patients will you recommend pegfilgrastim after chemotherapy? What goes into this decision making?
Added By: ben_adminWhat are the benefits of a pegfilgrastim auto injector?
Added By: ben_adminHow many patients will you recommend Udenyca for in the next 12 months?
Added By: ben_adminRank your excitement for Udenyca on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
